Adjusted relative risk of hepatic failure due to hepatitis B virus (HBV) reactivation after withdrawal of lamivudine according to various factors
| Variable | Adjusted relative risk (95%CI) | p Value |
|---|---|---|
| HBeAg, hepatitis B e antigen; CI, confidence interval. | ||
| ALT, alanine aminotransaminase (normal range 13–51 U/l). | ||
| HBV DNA ⩾104 copies/ml pre-chemotherapy | 0.345 | |
| Yes | 17.82 (0.56-35.78) | |
| No | 1 | |
| HBeAg pre-chemotherapy: | 0.616 | |
| Positive | 1.85 (0.17-20.53) | |
| Negative | 1 | |
| Elevated serum ALT pre-chemotherapy: | 0.746 | |
| Yes | 1.49 (0.13-16.87) | |
| No | 1 | |